ICLUSIG: payments to doctors
Payments that named ICLUSIG as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $3.2M
- Providers
- 5,700
- Transactions
- 12,753
- Average per transaction
- $249
The per-transaction average — $249 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,700 providers the average total is $556, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $3,028,964 | 95.5% |
| Otsuka Pharmaceutical Co., Ltd. | $121,762 | 3.8% |
| Incyte Corporation | $20,159 | 0.6% |
| Shire North American Group Inc | $94 | 0.0% |